Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CTRC | Q99895 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13488264 | 0.90 | PTGS2 (0.35) | MAOACYP1A2ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL13488276 | 0.89 | PTGS2 (0.34) | CYP1A2ALDH1A1CYP3A4CYP2C9HPGD | |
| SCHEMBL13488271 | 0.87 | MAOA (0.33) | CYP2A6MAOACYP1A2GPR84 | |
| SCHEMBL13488270 | 0.87 | GPR84 (0.35) | MAOAGPR84 | |
| SCHEMBL13304280 | 0.85 | GPR84 (0.34) | CYP1A2ALDH1A1CYP2C9TSHRSMN1; SMN2 | |
| SCHEMBL13147529 | 0.85 | ALDH1A1 (0.37) | CYP2A6TDP1MAOACYP1A2ALDH1A1 | |
| SCHEMBL12873466 | 0.83 | GPR84 (0.35) | CYP1A2ALDH1A1CYP2C9TSHRSMN1; SMN2 | |
| SCHEMBL13488580 | 0.82 | PADI4 (0.31) | — | |
| SCHEMBL365629 | 0.82 | CYP2A6 (0.55) | CYP2A6TDP1MAOACYP1A2ALDH1A1 | |
| SCHEMBL29353280 | 0.82 | CYP2A6 (0.55) | CYP2A6TDP1MAOACYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-25 | — | — | US | disclosed |
| EP-2108689-A2 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2009-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | OCIAD1, OCIAD2, ORMDL3 | CYP2A6 1410/4885TDP1 1904/4885MAOA 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.